AbbVie announced its Q2 2024 earnings will include $937 million in acquired IPR&D and milestones expense, resulting in an unfavorable impact of $0.52 to both GAAP and adjusted non-GAAP diluted EPS. The company has revised its full-year 2024 adjusted diluted EPS guidance to $10.61-$10.81, while Q2 2024 adjusted diluted EPS is expected to range between $2.53-$2.57.The revision reflects the incorporation of Q2 2024 IPR&D and milestones expense, bringing the total year-to-date expense to $1.101 billion. The previous guidance announced on April 26, 2024, had excluded the impact of such expenses beyond Q1 2024 due to the uncertainty in timing and occurrence of these transactions.The company notes that while these expenses may occur upon execution of collaborations, licensing agreements, and asset acquisitions, they cannot reliably forecast IPR&D and milestones expense beyond Q2 2024. The reported results for Q2 2024 remain subject to financial statement closing procedures.

AbbVie announced its Q2 2024 earnings will include $937 million in acquired IPR&D and milestones expense, resulting in an unfavorable impact of $0.52 to both GAAP and adjusted non-GAAP diluted EPS. The company has revised its full-year 2024 adjusted diluted EPS guidance to $10.61-$10.81, while Q2 2024 adjusted diluted EPS is expected to range between $2.53-$2.57.The revision reflects the incorporation of Q2 2024 IPR&D and milestones expense, bringing the total year-to-date expense to $1.101 billion. The previous guidance announced on April 26, 2024, had excluded the impact of such expenses beyond Q1 2024 due to the uncertainty in timing and occurrence of these transactions.The company notes that while these expenses may occur upon execution of collaborations, licensing agreements, and asset acquisitions, they cannot reliably forecast IPR&D and milestones expense beyond Q2 2024. The reported results for Q2 2024 remain subject to financial statement closing procedures.